Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Up 0.6%

Gilead Sciences stock opened at $130.50 on Wednesday. The company has a market capitalization of $162.02 billion, a price-to-earnings ratio of 17.78 and a beta of 0.31. The company’s fifty day moving average price is $137.18 and its two-hundred day moving average price is $133.48. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Scotiabank increased their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Wolfe Research increased their price target on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Finally, Truist Financial reaffirmed a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $156.62.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead was highlighted in a hedge-fund screen as one of the “best long-term low-risk stocks,” which may reinforce the view that institutional investors see it as a relatively defensive large-cap healthcare name. 5 Best Long Term Low Risk Stocks to Buy According to Hedge Funds
• Positive Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference, keeping investor focus on Gilead’s HIV, oncology, and pipeline outlook following its recent earnings beat. Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Positive Sentiment: Daiwa Securities lowered its price target to $150 from $161 but kept an Outperform rating, suggesting the firm still sees upside from current levels despite the cut.
• Positive Sentiment: Recent commentary around Gilead’s Q1 results pointed to solid execution, including strong HIV franchise performance and momentum in oncology, which supports the stock’s valuation. Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
• Neutral Sentiment: Gilead’s CFO and another senior insider disclosed stock sales, but both were made under pre-arranged 10b5-1 plans, which limits the bearish signal. Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock
• Negative Sentiment: Despite the constructive backdrop, analyst target cuts and insider selling may be creating some caution and helping cap gains in the near term.

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC grew its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Ieq Capital LLC grew its holdings in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after acquiring an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its holdings in shares of Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 674 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.